nLIGHT Q1 2026 slides: A&D surge drives record margins, profitability

nLIGHT posted a major Q1 2026 earnings beat, with revenue up 55% year over year to $80.2 million and non-GAAP EPS of $0.20, while Adjusted EBITDA surged to a record $13.8 million from $116,000 a year earlier. Aerospace & Defense revenue rose 69% to $55.1 million, driven by Directed Energy programs, and management guided Q2 revenue to $75 million-$81 million with continued A&D strength. Despite the strong fundamentals and $332.9 million cash position, shares fell 7.15% on the print before rebounding slightly aftermarket.

Analysis

LASR is shifting from a “hope story” to a capacity-and-contract execution story, which matters because the market usually re-rates defense growth only after it sees sustained conversion from bookings into product revenue and cash. The key second-order effect is that Directed Energy is no longer just an optionality narrative: it is beginning to crowd out the cyclicality of the industrial book, which should lower the multiple discount versus defense electronics peers if repeatable award cadence holds over the next 2-4 quarters.

The more interesting setup is not the reported quarter itself but the operating leverage embedded in the next few prints. With product mix driving margin expansion and working capital improving, incremental revenue should fall through at a much higher rate than the market likely modeled, creating a path for EBITDA revisions even if top-line growth normalizes. The main supply-chain implication is positive for specialized optics, lasers, and high-reliability subcomponents; the risk is that any bottleneck in scaling defense production could temporarily cap gross margin before demand does.

Consensus may be over-focusing on the post-earnings drawdown and underestimating that the balance sheet now gives management real optionality to front-load manufacturing investment ahead of awards rather than waiting for them. That can compress near-term FCF, but it also raises the probability of winning larger follow-on contracts by de-risking delivery timelines. The counter-risk is valuation: after a large run, the stock needs sustained defense revenue acceleration into mid-2026, not just a good quarter, or the multiple can de-rate quickly despite improving fundamentals.

Near term, the stock likely trades with high beta to any defense procurement headlines and broader risk appetite, but over 6-12 months the more durable catalyst is evidence that A&D revenue remains >60% of mix while product gross margin stays above the high-30s. If that happens, the market should stop treating LASR like a cyclical industrial and start pricing it closer to a defense growth compounder.

Key Decisions for Investors

• Initiate a tactical long in LASR over the next 3-5 trading days on post-earnings weakness, targeting a 3-6 month hold; thesis is multiple expansion from continued A&D mix shift and EBITDA revisions. Risk: if next quarter shows product gross margin reverting below the high-30s, cut quickly.
• Use LASR June/September call spreads rather than outright stock for event-driven upside; risk/reward is better if defense award headlines or guidance beats re-rate the name, while premium decay limits downside if the post-earnings gap fills.
• Pair LASR long against a basket of lower-quality industrial laser exposure over 1-2 quarters to isolate defense-end-market strength from general industrial cyclical noise. The trade works if the market continues rewarding differentiated government-tied growth and punishing slower private-sector demand.
• For existing holders, trim into strength only if the stock reclaims pre-earnings levels without a new contract catalyst; otherwise hold for a 6-12 month rerating as working capital improvements and cash-rich balance sheet support organic growth investment.
• Watch for a negative catalyst in 60-90 days: if management signals capex or inventory buildup is outrunning awards, reduce exposure because the market will likely punish any hint that growth is being manufactured ahead of demand.